NCT01178411 2021-03-10An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) ProtocolsArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Phase 1/2 Completed60 enrolled 11 charts